4.5 Article

Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.jaip.2021.07.056

Keywords

Asthma; Eosinophilic; Health care resource use; ISAR; Phenotypes; Primary care; Severity; United Kingdom

Funding

  1. AstraZeneca
  2. Boehringer Ingelheim
  3. GlaxoSmithKline
  4. Sanofi
  5. A. Menarini
  6. Alk-Albello
  7. Allergy Therapeutics
  8. Anallergo
  9. MedImmune
  10. Boeh-ringer Ingelheim
  11. Chiesi Farmaceutici
  12. Circassia
  13. Danone
  14. Faes
  15. Genentech
  16. Gui-dotti Malesci
  17. Hal Allergy
  18. Merck
  19. MSD
  20. Mundipharma
  21. Novartis
  22. Orion
  23. Sanofi Aventis
  24. Genzyme/Regeneron
  25. Stallergenes
  26. UCB Pharma
  27. Uriach Pharma
  28. Teva
  29. Thermo Fisher
  30. Valeas
  31. Genentech/Hoffman Roche

Ask authors/readers for more resources

The study found that the eosinophilic asthma phenotype predominates in primary care in the UK, and is associated with greater asthma severity and healthcare resource use. These patients may benefit from earlier and targeted asthma therapy.
BACKGROUND: We developed an eosinophil phenotype gradient algorithm and applied it to a large severe asthma cohort (International Severe Asthma Registry). OBJECTIVE: We sought to reapply this algorithm in a UK primary care asthma cohort, quantify the eosinophilic phenotype, and assess the relationship between the likelihood of an eosinophilic phenotype and asthma severity/health care resource use (HCRU). METHODS: Patients age 13 years and older with active asthma and blood eosinophil count or 1 or greater, who were included from the Optimum Patient Care Research Database and the Clinical Practice Research Datalink, were categorized according to the likelihood of eosinophilic phenotype using the International Severe Asthma Registry gradient eosinophilic algorithm. Patient demographic, clinical and HCRU characteristics were described for each phenotype. RESULTS: Of 241,006 patients, 50.3%, 22.2%, and 21.9% most likely (grade 3), likely (grade 2), and least likely (grade 1), respectively, had an eosinophilic phenotype, and 5.6% had a noneosinophilic phenotype (grade 0). Compared with patients with noneosinophilic asthma, those most likely to have an eosinophilic phenotype tended to have more comorbidities (percentage with Charlson comorbidity index of >= 2: 28.2% vs 6.9%) and experienced more asthma attacks (percentage with one or more attack: 24.8% vs 15.3%). These patients were also more likely to have asthma that was difficult to treat (31.1% vs 18.3%), to receive more intensive treatment (percentage on Global Initiative for Asthma 2020 step 4 or 5: 44.2% vs 27.5%), and greater HCRU (eg, 10.8 vs 7.9 general practitioner all-cause consultations per year). CONCLUSIONS: The eosinophilic asthma phenotype predominates in primary care and is associated with greater asthma severity and HCRU. These patients may benefit from earlier and targeted asthma therapy. (C) 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available